- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Multi-Patient CT Injection System from Bayer
Facilitating optimal use of contrast, the Medrad Centargo CT Injection System reportedly combines user-friendly features with workflow efficiency for high-volume CT departments.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Medrad Centargo CT Injection System, which enables contrast administration for multiple patients undergoing computed tomography (CT) exams.
Featuring a pre-assembled Day Set and a snap-in patient line that auto-primes upon insertion, the Medrad Centargo CT Injection System allows contrast set-up for multiple patients to be completed in less than two minutes, according to Bayer, the manufacturer of the Medrad Centargo CT Injection System.
The newly FDA-cleared Medrad Centargo CT Injection System reportedly allows contrast set-up for multiple patients to be completed in less than two minutes. (Photo courtesy of Bayer.)
For demanding CT protocols, Bayer said the system also has a Dual Flow feature that allows simultaneous administration of contrast and saline, which is facilitated by the Medrad Centargo CT Injection System’s piston-based technology.
The combination of automated documentation software and the system’s integrated barcode reader enables simplified access to contrast and injection details to help streamline reporting.
“We know radiologists today are facing a continuously increasing workload, and the automation, integration and mobility of the Medrad® Centargo CT Injection System helps radiology staff do more with less, allowing them more time to focus on their patients,” noted Sven Schmidt, the head of Region Americas Radiology at Bayer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
